|drug5||0.12% Chlorhexidine oral/nasal rinse Wiki||1.00|
|drug6||0.5% Povidone/Iodine oral/nasal rinse Wiki||1.00|
|D041881||Cholecystitis, Acute NIH||1.00|
|D042101||Acalculous Cholecystitis NIH||1.00|
There is one clinical trial.
For this study, 48 patients who have been diagnosed with COVID-19 will be randomly assigned to four study groups: control, saline, chlorhexidine gluconate, and povidone-iodine. Each patient will be asked to gargle with a solution of either saline, chlorhexidine gluconate, or povidone-iodine or nothing (control group) as well as spray the same solution in their nose four times daily. Patients will then be tested for COVID-19 once daily in the evening for 7 days and viral loads will be measured.
Description: nasopharyngeal swab for viral PCR will be taken at the end of each day for 7 daysMeasure: Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx Time: 7 days
Description: Recorded dailyMeasure: Oxygen requirement of the patient Time: 7 days
Description: Recorded dailyMeasure: Oxygen saturation of the patient Time: 7 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports